| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Collaboration revenue | 20,000 | NaN | NaN | |
| Research and development | 32,716 | 22,279 | 22,680 | |
| General and administrative | NaN | 7,707 | 6,816 | |
| Selling, general and administrative | 11,499 | NaN | NaN | |
| Total operating expenses | 44,215 | 29,986 | 29,496 | |
| Loss from operations | -24,215 | -29,986 | -29,496 | |
| Interest income | 4,358 | 3,061 | 2,764 | |
| Total other income, net | 4,358 | 3,061 | 2,764 | |
| Net loss | -19,857 | -26,925 | -26,732 | |
| Change in unrealized gains (losses) on investments, net of tax | -1,051 | 221 | 19 | |
| Total other comprehensive income (loss) | -1,051 | 221 | 19 | |
| Comprehensive loss | -20,908 | -26,704 | -26,713 | |
| Basic EPS | -0.42 | -0.71 | -0.75 | |
| Diluted EPS | -0.42 | -0.71 | -0.75 | |
| Basic Average Shares | 47,236,618 | 37,931,170 | 35,444,635 | |
| Diluted Average Shares | 47,236,618 | 37,931,170 | 35,444,635 | |
Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc. (RAPP)